Medicare negotiation carveouts named in Democrats' report on Trump holdings

What happened?

1. The report attributes up to $39.1 million of that 2025 value to companies the Democrats say benefited from exemptions to Medicare's drug price negotiation program created by the 2025 Republican tax and spending law.
2. Democrats on the committee pinpointed share acquisitions worth as much as $2.55 million in drugmakers that benefit from the exemption, occurring on three separate dates ahead of the bill’s signing in July 2025; July 1, 2025 saw up to $950,000 spent—the date the Senate approved the legislation.
3. The reports indicate that the White House denied ethics problems on multiple occasions and charged Democrats with trying to invent conflicts of interest.

Democrats on the Joint Economic Committee issued a report indicating that, as of the end of 2025, as much as $39.1 million worth of Trump’s pharmaceutical investments were held in firms that gained from carve‑outs to the Medicare drug‑pricing negotiation regime established by the 2025 tax‑and‑spending legislation. The analysis cites up to $2.55 million in purchases across three dates before the July 2025 signing and up to $1 million in AbbVie shares in August 2025. The White House denied any ethics issues.

A machine summary written from the reports listed below; read them for the full account. How summaries are made and what is checked.